Login / Signup

Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.

Shin FukudoA NakajimaY FujiyamaM KosakoA NakagawaH AkihoY NakashimaJ M JohnstonH Miwa
Published in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2017)
This study suggests that a linaclotide dose of 0.5 mg may be appropriate in Japanese patients with IBS-C.
Keyphrases
  • irritable bowel syndrome
  • double blind
  • phase ii
  • placebo controlled
  • clinical trial
  • open label
  • phase iii
  • study protocol
  • randomized controlled trial